Skip to main content
TipRanks
Go Ultimate75% OFF

Welgene Biotech Co., Ltd. (6661) AI Stock Analysis

TW:6661

Welgene Biotech Co., Ltd.

(TPEx:6661)

Select Model
Rating:38Underperform
Price Target:TWD 15.00▼(-0.99% Downside)
Action:initiatedcoverage
Date:11/10/26

The overall score of 38 is deeply bearish, driven primarily by a severe deterioration in financial performance. The company's inability to generate profit or positive free cash flow, coupled with a sharp increase in debt, presents a high-risk profile. This is compounded by a weak technical trend with the stock trading below all major moving averages and a negative P/E ratio that underscores the lack of earnings. The company is in a precarious financial position with no positive catalysts from valuation or market momentum.

Positive Factors
Revenue ReboundThe sharp 2025 revenue rebound shows that Welgene can regain demand after a softer period, supporting its ability to scale testing and laboratory services. If sustained, stronger volume can improve utilization, expand customer reach, and provide a larger base for future operating leverage.
Negative Factors
Thin ProfitabilityVery thin profitability leaves little buffer against cost increases, volume volatility, or changes in testing mix. Near-breakeven operating profit also indicates limited operating leverage today, making it harder for revenue growth to translate into durable earnings and internally funded expansion.

Welgene Biotech Co., Ltd. (6661) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%TW:6661-19.63%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 344.90M
Dividend Yield
―
Average Volume (3M)
5,499
Price to Earnings (P/E)
-30.5
Beta (1Y)
0.23
Revenue Growth
6.57%
EPS Growth
-822.48%
Country
TW
Employees
80
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Welgene Biotech Co., Ltd. Business Overview & Revenue Model

Company Description

Welgene Biotech Co.,Ltd. primarily focuses on delivering genetic analysis services. The company provides comprehensive support for scientific research, employing a range of advanced laboratory techniques such as genetic sequencing, microarray analysi...

Welgene Biotech Co., Ltd. Financial Statement Overview

Summary

Financial health is critically weak. The Income Statement (Score 28) shows collapsing profitability with a net margin of just 0.4% and eroding gross margins. The Cash Flow Statement (Score 18) is alarming, with negative free cash flow of -NT$6.1M, indicating the company cannot fund its investments internally. The Balance Sheet (Score 42) shows a concerning spike in debt-to-equity from 0.17 to 0.80, increasing financial risk. The overall trend is a severe deterioration in profitability and cash generation, funded by aggressive leveraging.

Income Statement

28Negative

Balance Sheet

42Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue398.92M375.94M322.55M280.55M321.90M312.65M
Gross Profit144.89M129.27M135.84M119.72M141.80M133.27M
EBITDA30.93M27.92M33.01M26.84M35.66M39.12M
Net Income-1.64M1.33M1.11M-2.65M9.55M13.70M
Balance Sheet
Total Assets658.59M622.19M528.25M548.16M435.71M424.54M
Cash, Cash Equivalents and Short-Term Investments201.99M269.03M228.19M197.83M218.36M224.26M
Total Debt281.15M226.03M129.83M154.35M51.19M23.84M
Total Liabilities380.96M336.12M232.50M247.89M131.76M114.47M
Stockholders Equity273.14M281.30M287.91M292.03M303.76M309.86M
Cash Flow
Free Cash Flow-102.42M-6.08M51.27M-28.10M24.57M6.87M
Operating Cash Flow29.09M35.27M56.08M-366.00K51.43M11.25M
Investing Cash Flow-127.35M-35.74M-45.19M6.00M-67.99M-10.34M
Financing Cash Flow85.35M51.31M-25.52M23.91M-24.61M38.52M

Welgene Biotech Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TW:6661 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:4183TW:418354NeutralTWD 345.10M-13.92―4.62%-23.50%-73.10%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TW:6661TW:666138UnderperformTWD 353.06M-30.49――6.57%-822.48%

* Healthcare Sector Average

Performance Comparison

-50%0%50%TW:6661TW:4117TW:4183TW:6660TW:6848TW:7595Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:6661 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:6661Welgene Biotech Co., Ltd.15.15-3.75-19.84%
TW:4117General Biologicals Corp.7.48-4.37-36.88%
TW:4183EPS Bio Technology Corp.14.50-2.55-14.96%
TW:6660HMD Biomedical, Inc.10.40-13.35-56.21%
TW:6848RBC Bioscience Corporation20.356.4446.26%
TW:7595Pharmigene, Inc.8.98-2.32-20.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026